Literature DB >> 19621425

Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response.

Sara Marino1, Federico Verzegnassi, Paolo Tamaro, Gabriele Stocco, Fiora Bartoli, Giuliana Decorti, Marco Rabusin.   

Abstract

BACKGROUND: Glucocorticoids (GCs) play a fundamental role in the treatment of pediatric acute lymphoblastic leukemia (ALL), but therapy with these agents often results in a number of severe side effects. The aim of our study was to evaluate the association between polymorphisms of genes encoding for proteins involved in the pharmacokinetics/pharmacodynamics of these drugs and the occurrence of side effects, in particular infections, in a small population of ALL children. PROCEDURE: Common polymorphisms of NR3C1, ABCB1, glutathione-S-transferase (GST)-M1, GST-P1, GST-T1, and IL-10 genes were analyzed in 36 pediatric patients with ALL, treated according to the AIEOP-BMF ALL 2000 study protocol. Toxicities occurring during the induction and reinduction periods were assessed and their association with genotypes was evaluated.
RESULTS: In univariate analysis, the risk of severe infections was increased in subjects with the GST-M1 null genotype, while patients with the GST-M1 normal genotype had significantly more moderate degree infections. The results were confirmed by multivariate analysis. Selection from the reference models of independent variables based on Akaike Information Criteria (AIC) scores maintained the GST-M1 genotype variable in the model to predict severe infections, and the ABCB1 C3435T and GST-M1 genotype variables in the model for moderate infections.
CONCLUSIONS: GST-M1 genotype may influence the severity of infections in ALL children during GC administration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19621425     DOI: 10.1002/pbc.22163

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  14 in total

Review 1.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Raffaella Franca; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

2.  Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

Authors:  Boris Labar; Stefan Suciu; Roel Willemze; Petra Muus; Jean-Pierre Marie; Georges Fillet; Zwi Berneman; Branimir Jaksic; Walter Feremans; Dominique Bron; Harm Sinnige; Martin Mistrik; Gerard Vreugdenhil; Robrecht De Bock; Damir Nemet; Caroline Gilotay; Sergio Amadori; Theo de Witte
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

Review 3.  Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.

Authors:  Lin Mei; Evelena P Ontiveros; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Blood Rev       Date:  2015-01-10       Impact factor: 8.250

4.  Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis.

Authors:  Ling Gu; Chenyan Zhou; Huajun Liu; Ju Gao; Qiang Li; Dezhi Mu; Zhigui Ma
Journal:  J Exp Clin Cancer Res       Date:  2010-11-18

5.  Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.

Authors:  R Franca; P Rebora; N Bertorello; F Fagioli; V Conter; A Biondi; A Colombini; C Micalizzi; M Zecca; R Parasole; F Petruzziello; G Basso; M C Putti; F Locatelli; P d'Adamo; M G Valsecchi; G Decorti; M Rabusin
Journal:  Pharmacogenomics J       Date:  2015-12-08       Impact factor: 3.550

6.  Glutathione s-transferases in pediatric cancer.

Authors:  Wen Luo; Michelle Kinsey; Joshua D Schiffman; Stephen L Lessnick
Journal:  Front Oncol       Date:  2011-10-24       Impact factor: 6.244

7.  Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines.

Authors:  Jianrong Wu; Huajun Liu; Ge Zhang; Ling Gu; Yanle Zhang; Ju Gao; Yuquan Wei; Zhigui Ma
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

8.  Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment.

Authors:  Meriç Kaymak Cihan; Halil Gürhan Karabulut; Nüket Yürür Kutlay; Hatice Ilgın Ruhi; Ajlan Tükün; Lale Olcay
Journal:  Turk J Haematol       Date:  2017-02-09       Impact factor: 1.831

9.  Epigenetic modifications and glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Authors:  Wilfred C de Vega; Santiago Herrera; Suzanne D Vernon; Patrick O McGowan
Journal:  BMC Med Genomics       Date:  2017-02-23       Impact factor: 3.063

10.  Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia.

Authors:  Gabriele Stocco; Raffaella Franca; Federico Verzegnassi; Margherita Londero; Marco Rabusin; Giuliana Decorti
Journal:  Front Genet       Date:  2013-01-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.